Aimée R Kreimer1, Paul Brennan1, Krystle A Lang Kuhs1, Tim Waterboer1, Gary Clifford1, Silvia Franceschi1, Angelika Michel1, Martina Willhauck-Fleckenstein1, Elio Riboli1, Xavier Castellsagué1, Allan Hildesheim1, Renée Turzanski Fortner1, Rudolf Kaaks1, Domenico Palli1, Ingrid Ljuslinder1, Salvatore Panico1, Françoise Clavel-Chapelon1, Marie-Christine Boutron-Ruault1, Sylvie Mesrine1, Antonia Trichopoulou1, Pagona Lagiou1, Dimitrios Trichopoulos1, Petra H Peeters1, Amanda J Cross1, H Bas Bueno-de-Mesquita1, Paolo Vineis1, Nerea Larrañaga1, Valeria Pala1, María-José Sánchez1, Carmen Navarro1, Aurelio Barricarte1, Rosario Tumino1, Kay-Tee Khaw1, Nicholas Wareham1, Heiner Boeing1, Annika Steffen1, Ruth C Travis1, J Ramón Quirós1, Elisabete Weiderpass1, Michael Pawlita1, Mattias Johansson1. 1. Aimée R. Kreimer, Krystle A. Lang Kuhs, and Allan Hildesheim, National Cancer Institute, National Institutes of Health, Bethesda, MD; Pagona Lagiou and Dimitrios Trichopoulos, Harvard School of Public Health, Boston, MA; Paul Brennan, Gary Clifford, Silvia Franceschi, and Mattias Johansson, International Agency for Research on Cancer, Lyon; Françoise Clavel-Chapelon, Marie-Christine Boutron-Ruault, and Sylvie Mesrine, Institut National de la Santé et de la Recherche Médicale, Centre for Research in Epidemiology and Population Health; Université Paris Sud; and Institut Gustave Roussy, Villejuif, France; Tim Waterboer, Angelika Michel, Martina Willhauck-Fleckenstein, Renée Turzanski Fortner, Rudolf Kaaks, and Michael Pawlita, German Cancer Research Center, Heidelberg; Heiner Boeing and Annika Steffen, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; Elio Riboli, Amanda J. Cross, H. Bas Bueno-de-Mesquita, and Paolo Vineis, School of Public Health, Imperial College, London; Kay-Tee Khaw and Nicholas Wareham, University of Cambridge, Cambridge; Ruth C. Travis, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Xavier Castellsagué, Institut Català d'Oncologia, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Consorcio de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), L'Hospitalet de Llobregat; Nerea Larrañaga, María-José Sánchez, Carmen Navarro, and Aurelio Barricarte, Consorcio de Investigación Biomédica en Red Epidemiología y Salud Pública, Madrid; María-José Sánchez, Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria, Hospitales Universitarios de Granada/Universidad de Granada, Granada; Carmen Navarro, Murcia Regional Health Council and Universidad de Murcia, Murcia; Aurelio Barricarte, Navarre Public Health Institute, Pamplona; J. Ramón Quirós, Public Health Directorate, Asturias; Nerea Larrañaga, Basque Regional Healt
Abstract
PURPOSE: Human papillomavirus (HPV) type 16 (HPV16) causes cancer at several anatomic sites. In the European Prospective Investigation Into Cancer and Nutrition study, HPV16 E6 seropositivity was present more than 10 years before oropharyngeal cancer diagnosis and was nearly absent in controls. The current study sought to evaluate the extent to which HPV16 E6 antibodies are present before diagnosis of anogenital cancers within the same cohort. METHODS: Four hundred incident anogenital cancers (273 cervical, 24 anal, 67 vulvar, 12 vaginal, and 24 penile cancers) with prediagnostic blood samples (collected on average 3 and 8 years before diagnosis for cervix and noncervix cancers, respectively) and 718 matched controls were included. Plasma was analyzed for antibodies against HPV16 E6 and multiple other HPV proteins and genotypes and evaluated in relation to risk using unconditional logistic regression. RESULTS: HPV16 E6 seropositivity was present in 29.2% of individuals (seven of 24 individuals) who later developed anal cancer compared with 0.6% of controls (four of 718 controls) who remained cancer free (odds ratio [OR], 75.9; 95% CI, 17.9 to 321). HPV16 E6 seropositivity was less common for cancers of the cervix (3.3%), vagina (8.3%), vulva (1.5%), and penis (8.3%). No associations were seen for non-type 16 HPV E6 antibodies, apart from anti-HPV58 E6 and anal cancer (OR, 6.8; 95% CI, 1.4 to 33.1). HPV16 E6 seropositivity tended to increase in blood samples drawn closer in time to cancer diagnosis. CONCLUSION: HPV16 E6 seropositivity is relatively common before diagnosis of anal cancer but rare for other HPV-related anogenital cancers.
PURPOSE: Human papillomavirus (HPV) type 16 (HPV16) causes cancer at several anatomic sites. In the European Prospective Investigation Into Cancer and Nutrition study, HPV16 E6 seropositivity was present more than 10 years before oropharyngeal cancer diagnosis and was nearly absent in controls. The current study sought to evaluate the extent to which HPV16 E6 antibodies are present before diagnosis of anogenital cancers within the same cohort. METHODS: Four hundred incident anogenital cancers (273 cervical, 24 anal, 67 vulvar, 12 vaginal, and 24 penile cancers) with prediagnostic blood samples (collected on average 3 and 8 years before diagnosis for cervix and noncervix cancers, respectively) and 718 matched controls were included. Plasma was analyzed for antibodies against HPV16 E6 and multiple other HPV proteins and genotypes and evaluated in relation to risk using unconditional logistic regression. RESULTS: HPV16 E6 seropositivity was present in 29.2% of individuals (seven of 24 individuals) who later developed anal cancer compared with 0.6% of controls (four of 718 controls) who remained cancer free (odds ratio [OR], 75.9; 95% CI, 17.9 to 321). HPV16 E6 seropositivity was less common for cancers of the cervix (3.3%), vagina (8.3%), vulva (1.5%), and penis (8.3%). No associations were seen for non-type 16 HPV E6 antibodies, apart from anti-HPV58 E6 and anal cancer (OR, 6.8; 95% CI, 1.4 to 33.1). HPV16 E6 seropositivity tended to increase in blood samples drawn closer in time to cancer diagnosis. CONCLUSION: HPV16 E6 seropositivity is relatively common before diagnosis of anal cancer but rare for other HPV-related anogenital cancers.
Authors: K Zumbach; F Kisseljov; O Sacharova; G Shaichaev; L Semjonova; L Pavlova; M Pawlita Journal: Int J Cancer Date: 2000-02-01 Impact factor: 7.396
Authors: Tim Waterboer; Peter Sehr; Kristina M Michael; Silvia Franceschi; John D Nieland; Thomas O Joos; Markus F Templin; Michael Pawlita Journal: Clin Chem Date: 2005-08-11 Impact factor: 8.327
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Silvia de Sanjose; Wim Gv Quint; Laia Alemany; Daan T Geraets; Jo Ellen Klaustermeier; Belen Lloveras; Sara Tous; Ana Felix; Luis Eduardo Bravo; Hai-Rim Shin; Carlos S Vallejos; Patricia Alonso de Ruiz; Marcus Aurelho Lima; Nuria Guimera; Omar Clavero; Maria Alejo; Antonio Llombart-Bosch; Chou Cheng-Yang; Silvio Alejandro Tatti; Elena Kasamatsu; Ermina Iljazovic; Michael Odida; Rodrigo Prado; Muhieddine Seoud; Magdalena Grce; Alp Usubutun; Asha Jain; Gustavo Adolfo Hernandez Suarez; Luis Estuardo Lombardi; Aekunbiola Banjo; Clara Menéndez; Efrén Javier Domingo; Julio Velasco; Ashrafun Nessa; Saibua C Bunnag Chichareon; You Lin Qiao; Enrique Lerma; Suzanne M Garland; Toshiyuki Sasagawa; Annabelle Ferrera; Doudja Hammouda; Luciano Mariani; Adela Pelayo; Ivo Steiner; Esther Oliva; Chris Jlm Meijer; Waleed Fahad Al-Jassar; Eugenia Cruz; Thomas C Wright; Ana Puras; Cecilia Ladines Llave; Maria Tzardi; Theodoros Agorastos; Victoria Garcia-Barriola; Christine Clavel; Jaume Ordi; Miguel Andújar; Xavier Castellsagué; Gloria I Sánchez; Andrzej Marcin Nowakowski; Jacob Bornstein; Nubia Muñoz; F Xavier Bosch Journal: Lancet Oncol Date: 2010-10-15 Impact factor: 41.316
Authors: Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Matti Lehtinen; Michael Pawlita; Klaus Zumbach; Katherine Lie; Matti Hakama; Egil Jellum; Pentti Koskela; Tapio Luostarinen; Jorma Paavonen; Eero Pukkala; Eva Sigstad; Steinar Thoresen; Joakim Dillner Journal: Am J Obstet Gynecol Date: 2003-01 Impact factor: 8.661
Authors: Hugo De Vuyst; Gary M Clifford; Maria Claudia Nascimento; Margaret M Madeleine; Silvia Franceschi Journal: Int J Cancer Date: 2009-04-01 Impact factor: 7.396
Authors: E Riboli; K J Hunt; N Slimani; P Ferrari; T Norat; M Fahey; U R Charrondière; B Hémon; C Casagrande; J Vignat; K Overvad; A Tjønneland; F Clavel-Chapelon; A Thiébaut; J Wahrendorf; H Boeing; D Trichopoulos; A Trichopoulou; P Vineis; D Palli; H B Bueno-De-Mesquita; P H M Peeters; E Lund; D Engeset; C A González; A Barricarte; G Berglund; G Hallmans; N E Day; T J Key; R Kaaks; R Saracci Journal: Public Health Nutr Date: 2002-12 Impact factor: 4.022
Authors: Brenda Y Hernandez; Marc T Goodman; Elizabeth R Unger; Martin Steinau; Amy Powers; Charles F Lynch; Wendy Cozen; Maria Sibug Saber; Edward S Peters; Edward J Wilkinson; Glenn Copeland; Claudia Hopenhayn; Youjie Huang; Meg Watson; Sean F Altekruse; Christopher Lyu; Mona Saraiya Journal: Front Oncol Date: 2014-02-05 Impact factor: 5.738
Authors: Julia M L Brotherton; Mark Jit; Patti E Gravitt; Marc Brisson; Aimée R Kreimer; Sara I Pai; Carole Fakhry; Joseph Monsonego; Silvia Franceschi Journal: Int J Cancer Date: 2016-03-22 Impact factor: 7.396
Authors: Gypsyamber D'Souza; Gwendolyn Clemens; Tanya Troy; Rachel G Castillo; Linda Struijk; Tim Waterboer; Noemi Bender; Phillip M Pierorazio; Simon R Best; Howard Strickler; Dorothy J Wiley; Robert I Haddad; Marshall Posner; Carole Fakhry Journal: Cancer Prev Res (Phila) Date: 2019-08-16
Authors: Karen S Anderson; Garrick Wallstrom; Hilde Langseth; Marshall Posner; Julia N Cheng; Rizwan Alam; Diego Chowell; Ingegerd E Furre; Jon Mork Journal: Oral Oncol Date: 2017-09-01 Impact factor: 5.337
Authors: Yuehan Zhang; Tim Waterboer; Robert I Haddad; Brett A Miles; Alicia Wentz; Neil D Gross; Carole Fakhry; Harry Quon; Jochen H Lorch; Christine G Gourin; Daniel Clayburgh; Krzysztof J Misiukiewicz; Jeremy D Richmon; Peter E Andersen; Marshall R Posner; Gypsyamber D'Souza Journal: Oral Oncol Date: 2017-02-15 Impact factor: 5.337
Authors: Till Piontek; Christoph Harmel; Michael Pawlita; Katrin Carow; Juliane Schröter; Ingo B Runnebaum; Matthias Dürst; Frederik Graw; Tim Waterboer Journal: Philos Trans R Soc Lond B Biol Sci Date: 2019-05-27 Impact factor: 6.237
Authors: Virginia E Drake; Carole Fakhry; Melina J Windon; C Matthew Stewart; Lee Akst; Alexander Hillel; Wade Chien; Patrick Ha; Brett Miles; Christine G Gourin; Rajarsi Mandal; Wojciech K Mydlarz; Lisa Rooper; Tanya Troy; Siddhartha Yavvari; Tim Waterboer; Nicole Brenner; David W Eisele; Gypsyamber D'Souza Journal: Cancer Date: 2021-01-11 Impact factor: 6.860
Authors: Helen C Stankiewicz Karita; Tim Waterboer; Amalia Magaret; David R Doody; Michael Pawlita; Nicole Brenner; Denise A Galloway; Anna Wald; Margaret M Madeleine Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-09-03 Impact factor: 4.090